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Abstract
Gamma delta T cells (GDTc) lyse a variety of hematological and solid tumour cells in vitro and in vivo, and are thus promising
candidates for cellular immunotherapy. We have developed a protocol to expand human GDTc in vitro, yielding highly
cytotoxic Vgamma9/Vdelta2 CD27/CD45RA double negative effector memory cells. These cells express CD16, CD45RO,
CD56, CD95 and NKG2D. Flow cytometric, clonogenic, and chromium release assays confirmed their specific cytotoxicity
against Ph
+ cell lines in vitro. We have generated a fluorescent and bioluminescent Ph
+ cell line, EM-2eGFPluc, and
established a novel xenogeneic leukemia model. Intravenous injection of EM-2eGFPluc into NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ (NSG) mice resulted in significant dose-dependent bone marrow engraftment; lower levels engrafted in blood, lung, liver
and spleen. In vitro-expanded human GDTc injected intraperitoneally were found at higher levels in blood and organs
compared to those injected intravenously; GDTc survived at least 33 days post-injection. In therapy experiments, we
documented decreased bone marrow leukemia burden in mice treated with GDTc. Live GDTc were found in spleen and
bone marrow at endpoint, suggesting the potential usefulness of this therapy.
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Introduction
Gamma delta T cells (GDTc) are immunosurveillance cells,
involved in both innate and adaptive immunity. GDTc are
promising candidates for adoptive immunotherapy because they
elicit cytolytic responses against a variety of allogeneic and
autologous tumors in vitro and in vivo [1,2,3,4,5]. Most GDTc
circulating in the peripheral blood are of the Vc9Vd2 subset; they
recognize and are activated by a number of hematological
malignancies [6,7,8,9]. Indeed, disease status in acute myeloid
leukemia patients was found to correlate with circulating GDTc
levels [10]. Likewise, elevated GDTc counts correlated with
improved disease-free survival in leukemia patients following T
cell-depleted allogeneic bone marrow transplantation [11];
furthermore, this GDTc increase was sustained over several years
[12].
A pilot study adoptively transferring autologous GDTc into
patients with advanced renal cell carcinoma by Kobayashi et al
was without severe adverse effects and showed that an increase in
peripheral blood GDTc correlated with prolonged tumor doubling
times [13]. The same group recently reported on a patient in
complete remission two years after autologous, in vitro-expanded
GDTc therapy, which eradicated multiple lung metastases [14]. In
a recent Phase I trial, autologous ex vivo-expanded GDTc were
infused into patients with recurrent non-small-cell lung cancer;
GDTc were well tolerated, however, efficacy could not be
determined due to the small cohort size (n=10) [15]. In the few
patients treated to date however, infusion of autologous in vitro
expanded cytotoxic GDTc appears safe and may constitute novel
therapy to eradicate various hematological malignancies.
Ph+ leukemia arises from the fusion of bcr and abl genes
[16,17,18]. Treatment with imatinib mesylate (IM), a tyrosine
kinase inhibitor (TKI) that targets p210
Bcr-Abl [19] constitutes
standard of care for newly diagnosed CML patients [20]. While
the majority achieves a complete cytogenetic response and the
restoration of normal hematopoiesis, lifetime therapy with TKIs is
required for most because quiescent malignant CML clones are
not eradicated by the treatment [21]. Although second- and third-
generation TKIs may offer improved efficacy over IM, none are
yet able to definitively cure CML [22]. Mustjoki recently reported
eradication of most Ph+ progenitors in chronic phase CML
patients on TKIs, but suggested that anti-CML immune control
dictates remission in patients discontinuing TKI therapy [23].
Thus, it is important to develop novel therapeutic approaches that
bolster the immune system to attain complete disease eradication.
This approach is especially important for patients presenting with
TKI-refractory disease. CML is responsive to immunotherapeutic
approaches, as evidenced by positive outcomes after donor
lymphocyte infusion and earlier studies with interferon alpha.
Furthermore, vaccination of CML patients with a multipeptide
targeting the p210 fusion protein improved cytogenetic responses
[24]. Moreover, immunotherapy that can eliminate TKI-induced
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perhaps cure.
Kreutzman et al recently showed that clonal lymphocytes,
including GDTc, existing in CML patients at diagnosis specifically
expand in the context of dasatinib therapy [25]. In conjunction
with earlier studies correlating clonal lymphocyte expansions with
positive clinical outcome [26], this suggests an anti-leukemia role
for clonal GDTc in vivo. We have developed a protocol to expand
human GDTc in vitro and confirmed their selective cytotoxicity to
Ph
+ leukemia cell lines. We have also established a novel
xenogeneic model with bioluminescent leukemia cells to test
GDTc therapy in vivo.
Materials and Methods
Ethics statement
Human blood samples were collected from healthy adult donors
after obtaining written informed consent according to UHN
Research Ethics Board approved protocols. This study was
approved by the institutional Animal Care Committee of the
University Health Network (Permit Number: 917.9), and carried
out in accordance with the Canadian Council on Animal Care
Guidelines.
Cells
Primary GDTc. Peripheral blood mononuclear cells
(PBMCs) were recovered using density gradient separation
(Ficoll-Paque, GE Healthcare, Piscataway NJ). GDTc were
enriched from the PBMC fraction by magnetic sorting using the
Miltenyi cd T cell positive selection kit (Miltenyi Biotec, Auburn
CA) as per the manufacturer’s instructions. GDTc were eluted into
complete medium containing 1 mg/ml Concanavalin A (ConA,
Sigma-Aldrich, Oakville ON) then plated at 2.5610
5/ml in 24-
well plates. Complete medium: AIM-V (Gibco) with 5% human
AB serum (Lonza, Walkersville, MD), 10 ng/ml each recombinant
human IL-2 (rIL-2, Proleukin, Novartis Pharmaceuticals, Canada)
and IL-4 (R&D Systems, Minneapolis, MN). Donor cells were
cultured for 6–8 days in ConA, reaching exponential growth.
They were then harvested, media containing ConA was removed
and GDTc were further cultured in complete medium (above)
without ConA. Cell enumeration and viability were assessed by
use of a hemocytometer and Trypan blue exclusion. Cells were re-
plated in fresh complete medium at 2.5610
5/ml or 5.0610
5/ml in
24-well plates and maintained in a humidified atmosphere at 37uC
with 5% CO2.
Cell Lines. The Ph
+ myeloid cell line K562 and Burkitt
Lymphoma line Raji were obtained from the American Type
Culture Centre (ATCC) (Manassas, VA). The Ph+ myeloid
leukemia cell line, EM-2, was derived from a patient with CML
relapsing with a Ph+ myeloid blast crisis after allogeneic bone
marrow transplantation; this line has been available in our lab
since the 1980s [27]. EM-2eGFPluc and RAJIeGFPluc were
generated as described below.
Lentivirus Production and Cell Transduction
A lentiviral vector (LV) encoding the cDNAs for enhanced GFP
and luciferase (eGFPluc) (pCCL.sin.cPPT.polyA.CTE.eGFP.
minhCMV.hPGK.luc.WPRE) was constructed using a dual
promoter system. Expression of eGFP was driven by the minimal
human CMV (minhCMV) promoter and luciferase expression was
driven by the human phosphoglycerate kinase (hPGK) promoter.
The parent vector containing a different dual promoter system was
originally obtained from Dr. L. Naldini [28]; the truncated version
of low-affinity NGF receptor (DLNGFR) in that parent construct
was replaced by the firefly luciferase cDNA by standard molecular
biology techniques. Recombinant leiviral virions were generated
following our protocol [29] with few modifications. Briefly, 293T
cells were transiently transfected using a three-plasmid packaging
system (LV plasmid construct, the packaging plasmid
pCMVR8.91, and the vesicular stomatitis virus glycoprotein
envelope-coding plasmid pMD.G) in the presence of polyethyle-
nimine (PEI). Viral supernatants were harvested at 24 and
48 hours post-transfection and concentrated by ultracentrifuga-
tion. The concentrated viral supernatants were serially diluted and
functionally titered on 293T cells; productively transduced cells
were enumerated by flow cytometry (data not shown). A functional
titer of ,3610
8 infectious particles/ml was obtained after
concentration. EM-2 and RAJI cells were transduced with the
eGFPluc LV at an effective MOI of 1; positive cells were sorted by
flow cytometry for eGFP expression, expanded and then frozen
and stored in liquid nitrogen until required.
CD107 Assays. 1610
5 GDTc were mixed with 5610
5 target
cells in AIM V complete media in a 96-well round bottom plate.
5 ml anti-CD107Alexa647 (Biolegend, H4A3) was added to all
wells to a final concentration of 10 mg/ml. As a positive control,
0.15 nM PMA (Sigma-Aldrich, Oakville ON) and 0.3 mg/ml
Ionomycin (Sigma-Aldrich, Oakville ON) were added to one well.
Cells were incubated for 1 h at 37uC. Subsequently, 8.5 mlo fa
1:50 dilution of Golgi stop (BD Biosciences) was added to a final
concentration of 2.6 mM. Incubation continued at 37uC for 2 h,
after which cells were placed in the dark on ice. Further staining
was performed as described in ‘Flow cytometry’.
Bioluminescent imaging (BLI)
Cells. EM-2eGFPluc were re-suspended in PBS such that the
total cell number was 1.25610
5 cells in the first well, then serial
dilutions were performed 1:2 in PBS for 7 wells of a 96-well flat-
bottomed plate. 100 ml luciferin was added to 100 ml cell
suspension in a 96-well flat bottom to a final concentration of
150 mg/ml and imaging performed a minimum of 5 minutes later
using the IVISH imaging system (Xenogen, Alameda, CA).
Regions of interest were identified and luminescence was
quantified using IVISH technology and LivingImage
TM software
(Xenogen). Linear regression analyses were calculated using Excel.
Mice. Luciferin was injected IP at 150 mg/kg 10–15 min
prior to scanning. Mice were anesthetized using 3–4% isofluorane
administered via the Xenogen vaporiser, until loss of consciousness
and then they were maintained at 1.5–2% isofluorane. The IVISH
imaging system and Living Image
TM software were used to
acquire the images and quantify bioluminescence as above.
Flow cytometry. Fluorescence-activated cell sorting (FACS)
was performed on a FACS Calibur (Becton Dickenson,
Mississauga ON), calibrated with CaliBRITE Beads (Becton
Dickenson, Mississauga ON), and data was analyzed with
CellQuest
TM Software (Becton Dickenson, Mississauga ON)
where indicated. Viability was determined with 7-AAD (Sigma-
Aldrich, Oakville ON, 5 ml/sample). All other flow cytometry was
done using the FC-500 (Beckman-Coulter) and analysis was
performed using FlowJo
 software.
Antibodies. The following antibodies were used for GDTc
immunophenotyping: anti-CD3 APC (BioLegend, UCHT1,
0.5 mg/ml), anti-CD16 PE (BioLegend, 3G8, 2.5 mg/ml), anti-
CD27 APC (BD Biosciences, M-T271, 0.5 mg/ml), anti-CD45RA
FITC (BD PharMingen, H1 100, 5 mg/ml), anti-CD45RO PE (BD
PharMingen, UCHL1, 1.25 mg/ml), anti-CD56 FITC (BioLegend,
MEM-188, 5 mg/ml), anti-CD95PE (BD Biosciences, DX2,
2.5 mg/ml), anti-NKG2D PE (R&D Systems, 149810, 0.5 mg/ml),
anti-TCR alpha/beta FITC (BD Biosciences, T10B9.1A-31,
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anti-TCR gamma/delta PE (eBiosciences, B1.1, 20 mg/ml), anti-
Vgamma9biotin(1:10,kind gift ofDr.LiZhang,UHN)followed by
streptavidin-APC (eBiosciences, 0.2 mg/ml) and anti-Vdelta2PE
(BioLegend, B6, 0.25 mg/ml). Annexin V-FITC (Biovision,
Mountain View CA, 5 ml=0.75 mg/sample) and 7-AAD (Sigma-
Aldrich, Oakville ON, 5 ml=5mg/sample) were used in the flow
cytometry-based cytotoxicity assays (see below). To detect GDTc in
mouse blood and tissues, we used anti-CD3 APC (BioLegend,
UCHT1, 0.5 mg/ml) and anti-CD45-PE (BioLegend, H130,
0.15 mg/ml). All antibodies were diluted in 20 ml FACS buffer
(PBS +1% FBS +2 mM EDTA).
Cytotoxicity Assays
The flow cytometric cytotoxicity assay was carried out as
described [30]. In brief, K562 cells were subject to membrane
staining with 3 mM PKH-26 dye (Sigma-Aldrich, Oakville ON) as
follows. Cells were mixed with an equivalent volume of 26PKH-
26 stock solution, then incubated 4 min at room temperature with
periodic inversion. An equal volume of serum was added, cells
were incubated for 1 min to stop the reaction followed by dilution
with an equivalent volume of complete medium. Cells were then
spun for 10 min at 4006g. Cells were transferred to a fresh tube,
washed, resuspended and then plated into 96-well round bottom
plates, to which GDTc were added at a 20:1 effector:target ratio in
a final volume of 200 ml in RPMI 1% BSA (GIBCO Canada Ltd,
Burlington ON), and 150 U/ml rIL-2 (Chiron, Ville Saint-
Laurent, Quebec). Incubation was for 4 hours at 37 degrees, 5%
CO2. Cells were then stained with Annexin V-FITC (Biovision,
Mountain View CA) and 7-AAD (Sigma-Aldrich, Oakville ON)
and subjected to flow cytometry-based analyses. Percentages of
Annexin V-positive cells at 4 hours were calculated by subtracting
the mean percentage of Annexin V-positive target cells at t=0
from that at t=4 hours and dividing by the total effector cell
number at t=0. SEM was calculated and statistical analysis
performed with Excel software.
Colony-forming cell (CFC) assay
10,000 autologous PBMCs were incubated with 200,000 GDTc
(mean purity =97.8%) in 200 ml RPMI 1% BSA and 150 U/ml
rIL-2 at 37uC with 5% CO2. After four hours, GDTc were
depleted as described below. PBMCs were cultured in Methyl
Cellulose H443 (Stem Cell Technologies, Vancouver, BC), seeded
at a density of 150 000 cells/plate in triplicate, according to the
manufacturer’s instructions for 2 weeks prior to colony counting.
GDTc depletion
Prior to plating cells in Methyl Cellulose H443, GDTc were
stained and depleted using the TCR cd isolation kit (Miltenyi
Biotec, Auburn CA) as per the manufacturer’s instructions.
Following cell labeling, cells were run through an LD depletion
column and washed three times with MACS buffer. Cells in the
flow-through were then enumerated and plated in Methyl
Cellulose H443 (Stem Cell Technologies, Vancouver, BC)
according to the manufacturer’s instructions for 14 days at 37uC
with 5% CO2.
Chromium Release Assay
Cr
51 release assays were performed according to standard
protocols [31]. Data are presented as mean % lysis of duplicate or
triplicate samples as indicated (6SD).
Mice. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(Jackson Laboratories, Bar Harbor, ME) were maintained at the
Ontario Cancer Institute animal facility. 8–12 week old males
were irradiated (250 cGy,
137Cs) 4–24 hours prior to tail vein
injection of the indicated number of EM-2eGFPluc cells in a final
volume of 0.2 ml PBS +0.2% BSA. GDTc were injected
intravenously or intraperitoneally (IP) at the indicated doses and
timepoints. rIL-2 (Proleukin, Novartis Pharmaceuticals, Canada)
was administered (100 IU/mouse) IP concordant with the GDTc
injections and weekly thereafter where indicated. Leukemia
progression/regression was monitored via IVISH imaging. Mice
were evaluated frequently for symptoms of leukemia and all efforts
made to minimize suffering; animals were sacrificed at appropriate
humane endpoints.
Preparation of blood and tissues for flow cytometry
Using a heparinized capillary tube, approximately 50 ml of blood
was obtained from the saphenous vein of each mouse. 1.5 ml of
ACK red blood cell lysis buffer (0.155 M NH4Cl, 10 mM KHC03,
0.1 mM Na2EDTA in distilled H20) was added and cells were
incubated for 10 min at room temperature with frequent vortexing.
Cells were centrifuged for 5 min at 4006g, supernatants removed
and then the pellets re-suspended in 10 ml mouse IgG (1:100,
Sigma-Aldrich, Oakville ON) in FACS buffer and incubated for
10 min on ice in the dark. Anti-CD3 APC and anti-CD45 PE
antibodies were added to final concentrations of 0.5 mg/ml and
0.15 mg/ml, respectively, in 20 ml final volume. Cells were stained
for 20 min on ice in the dark, followed by washing with 1 ml FACS
buffer,then fixingwith 2%paraformaldehydeinFACS buffer. Cells
were strained through a fine mesh before flow cytometric
acquisition. Organs were removed from the animals and placed in
PBS +1% FCS solution on ice. Tissues were homogenized by
placing small pieces between mesh squares in PBS +1% FCS and
scraping with forceps; aliquots were removed for further processing.
ACK lysis and staining were performed as described above.
Statistics. Kaplan-Meier survival curves, Logrank tests and
student’s t tests were performed with GRAPHPAD PRISM 5 for
Windows (version 5.03).
Results
Gamma delta T cells isolated from human blood can be
expanded in vitro and have a predominantly effector
memory phenotype
We have developed a protocol to obtain high yields and purity of
GDTc isolated from healthy donor-derived peripheral blood
mononuclear cells (PBMCs). Expansion yields from a single donor
(Donor 1) were variable, ranging from 29-fold to 832-fold (Fig. 1a).
%Vdelta2 (Vd2) for these expansions were greater than 74%. Please
see Supplementary Table S1 for more information about these
cultures, and Supplementary Figures S1, S2, S3, S4 and S5 for
supporting flow cytometry data. The majority of the expanded
cultures comprised CD27- and CD45RA-negative effector memory
cells (Fig. 1b), as defined by Dieli et al [32]. A representative example
of flow cytometry performed on days 15 and 21 of culture is shown in
Fig. 1b. Examination of histogram overlays shows that expression of
all markers decreased only slightly from d15 to d21. For example, the
activation marker CD56 was virtually unchanged, from a 12.6-fold
mean fluorescence intensity increaseover unstained on d15 to a 10.9-
fold increase on day 21. Histograms show that the memory marker
CD45RO was highly expressed (92% and 87%), as was CD95 (Fas,
99% and 94%). CD16 expression was variable, at 46%+ on d15 to
30%+on d21. Cells were 92% Vd2+and 80% NKG2D+on d15 and
similarly 85% Vd2+and77%NKG2D+on day 21. High TCR levels
were evidenced by CD3 expression (94% and 89%, respectively).
Please see Supplementary Table S2 for percentages and mfi values;
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16700Figure 1. Human Vgamma9 Vdelta2 gamma delta T cells expanded in vitro have an effector memory phenotype. a) Fold expansion
data for gamma delta T cell cultures derived from a single donor exhibit variable yet high yields. The isolation number (#6, #11, #13, #25, #34) is
indicated; cultures shown were derived from the same donor at different times, a minimum of 2 months apart. b) Expanded cells from culture #25
were harvested on days 15 and 21, then stained for the indicated surface markers and subject to flow cytometry. % live cells which stained for CD27
and/or CD45RA are shown on the dot plots. Histogram overlays show the indicated marker expression as % maximum. CD56 expression is displayed
for stained and unstained cells on days 15 and 21 as indicated above the respective panels; –fold mean fluorescence intensity over the unstained
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antibody. Vd2 cells were all Vgamma9 (Fig. 1c, n=3 different
donors, shown is a representative example).
Expanded gamma delta T cells are selectively cytotoxic
against Ph
+ leukemia cell lines and not autologous
hematopoietic progenitors
GDTc isolated from nine healthy donors were expanded in vitro
and then co-incubated with K562 or EM-2 cells or autologous
PBMCs at a 20:1 effector to target (E:T) ratio for 4 hours. The
percentage of apoptotic EM-2 cells was 45% 63% (mean 6 SE)
compared to 27% 62% for K562 cells and only 0.4% 61.1% for
PBMCs as identified by Annexin V staining and flow cytometric
analysis (Fig. 2a). Focusing on the live target cell population in this
assay, which was both AnnexinV and 7-AAD negative, and
applying the formula: % lysis = [(%live targett=0 - %live
targett=4 hours)/(%live targett=0)] 6100% yielded 52% 62%
EM-2, 40% 64% K562 and 2% 62% PBMCs (Fig. 2a). Thus,
incubation of autologous PBMC with GDTc did not result in
significant lysis of PBMCs, but GDTc are selectively cytotoxic
against these Ph
+ leukemic cell lines.
Figure 2. Expanded gamma delta T cells are selectively cytotoxic against Ph
+ leukemia cells and not autologous hematopoietic
progenitors. a) Gamma delta T cells are selectively cytotoxic against Ph
+ leukemia cell lines K562 and EM-2, but not against normal autologous
hematopoietic progenitors, as assessed by a flow cytometric cytotoxicity assay (n=9 different donors, minimum 6 replicates/donor). Gamma delta T
cells were incubated with target cells for 4 hours at an effector:target ratio of 20:1. Mean % AnnexinV and %lysis 6 standard error of target cells is
shown. Data were acquired via FACSCalibur and analysed with CellQuest
TM software. b) Co-culture of gamma delta T cells with PBMCs does not
adversely affect PBMC growth. 200,000 gamma delta T cells were co-incubated with 10,000 autolougous PBMC at 20:1 effector:target ratio for 0 or
4 hours as indicated. Subsequently, gamma delta T cells were depleted and of the remaining cells, 150,000 per plate were seeded in triplicate for
colony-forming assays for normal hematopoietic progenitors, BFU-E and CFU-GM (n=3 different donors in triplicate).
doi:10.1371/journal.pone.0016700.g002
control is indicated. Histogram overlays show expression of markers CD45RO, CD95, NKG2D, CD16, Vdelta2 TCR and CD3 on day 15 (blue) and day 21
(green), with an unstained sample serving as negative control (red). Shown is a representative example; (n=8, 2 different donors). c) A representative
flow cytometric analysis of expanded gamma delta T cells indicates that Vdelta2 is paired with Vgamma9 (n=3 different donors). Cells were
harvested and stained with anti-Vgamma9 biotin antibody, followed by anti-streptavidin-APC and anti-Vdelta2PE antibodies.
doi:10.1371/journal.pone.0016700.g001
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etic progenitors, GDTc were co-incubated with autologous
PBMCs for 4 hours and compared to a 0 hour control.
Enumeration of early erythroid (BFU-E) and granulocyte-
macrophage colonies (CFU-GM) derived from cells at both time
points demonstrated comparable colony numbers (Fig. 2b),
verifying that GDTc are not cytotoxic towards the autologous
hematopoietic progenitors.
EM-2eGFPluc cells are fluorescent and bioluminescent
In order to test GDTc therapy in a pre-clinical setting, we
developed a xenogeneic model of Ph
+ leukemia using fluorescent
and bioluminescent leukemia cells. For this, we first transduced
EM-2 with a lentiviral vector encoding enhanced green fluorescent
protein (eGFP) and luciferase. The recombinant lentivector was
constructed such that a dual promoter system drives eGFP and
Luciferase expression in transduced cells (Fig. 3a). Flow cytometry
was performed on EM-2 and the transduced cells to confirm that
EM-2eGFPluc are fluorescent (Fig. 3b). We subjected serially
diluted cells to bioluminescent imaging to confirm that EM-
2eGFPluc bioluminescence is directly proportional to cell number
(Fig. 3c, linear regression =0.9965).
Transduction of the parental line did not affect the ability of
GDTc to recognize and become activated by these targets
(Supplementary Fig. S7). Likewise, transduction of the vector into
RAJI cells, which do not activate GDTs, did not result in CD107
expression of GDTc (Supplementary Fig. S8).
A novel xenogeneic bioluminescent Ph
+ leukemia model
We have established a xenogeneic mouse model of Ph
+
leukemia by injecting EM-2eGFPluc cells intravenously (iv) into
non-lethally irradiated NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
Figure 3. EM-2eGFPluc cells are fluorescent and bioluminescent. a) Scheme of the recombinant lentivector constructed for these studies
showing the dual promoter system driving eGFP and Luciferase expression in transduced cells. b) The parental cell line, EM-2, and transduced line,
EM-2eGFPluc, were subject to flow cytometry. Shown is a representative example. Cells were assessed by flow cytometry prior to each injection into
NSG mice (n=9). c) EM2eGFPluc cell bioluminescence directly correlates with cell number. Cells were harvested and density adjusted in PBS, then
subject to serial dilution 1:2 from well to well. After addition of luciferin, cells were imaged using IVISH technology and then quantified using Living
Image
TM software. Luminescence was plotted against cell number and linear regression calculated using Microsoft Excel software (n=2).
doi:10.1371/journal.pone.0016700.g003
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consistent bone marrow engraftment, we irradiated 8.5-week old
mice with 2.5 Gy one day prior to leukemia cell injection. We then
injected 1–10610
5 EM-2eGFPluc cells iv (3 mice at each dose of
1, 2.5, 5, 7.5 and 10610
5 plus 1 PBS control) and monitored
engraftment via in vivo (IVIS) imaging at 21, 28 and 32 days post-
injection. On d21, 5 minute scans showed luciferase signals
corresponding to bone marrow engraftment. Shown here is a
representative scan of 3 mice that received 2.5 and 2 mice with
1610
5 EM-2eGFPluc (Fig. 4a). Consistent engraftment of
leukemia cells in the bone marrow of both hind limbs was evident
even in mice injected with the lowest EM-2eGFPluc dose of 1610
5
cells. Bone marrow signals from scans performed on d28 were
quantified using Living Image
TM software and plotted against
injected cell number, revealing that EM-2eGFPluc engrafted bone
marrow in a dose-dependent manner (Fig. 4b).
Gamma delta T cells persist and remain viable in our
xenogeneic leukemia model
We then investigated the viability and biodistribution of human
GDTc effector cells in this model. We initially injected GDTc iv
and were able to detect these cells in the mice until the
experimental endpoint (data not shown); however, we wanted to
see whether we could further enhance levels by injecting GDTs
intraperitoneally (ip). Indeed, we found more ip-injected than iv-
injected GDTs in our established leukemia model (Fig. 5a). We
irradiated mice in the evening prior to injection day and then
injected six animals with 1.5610
6 EM-2eGFPluc cells iv and three
animals with PBS. Six days later, 2 groups of 3 tumour-bearing
mice each were injected with 30610
6 expanded GDTc from
Donor 2 either iv or ip. The remaining three mice were injected
with GDT iv and constituted the ‘‘GDT only’’ group. Mice were
sacrificed on day 20; blood and tissues were processed for flow
cytometry. The data show more ip-injected than iv-injected GDTc
in all tissues analyzed (Fig. 5a). It is noteworthy that none of the
mice receiving 30610
6 GDTc developed graft-versus-host disease
(GvHD), proving that at least one dose of large numbers of human
GDTc were well tolerated in NSG mice.
In early therapy experiments, we had injected 1.5610
6 EM-
2eGFPluc cells iv into NSG mice to establish leukemia and then
administered GDTc therapy at various time points and doses, in
an attempt to halt leukemia progression. In one such experiment,
30610
6 Donor 1 GDTc were injected iv on days 6 and 12 post-
leukemia cell injection, along with 100 IU recombinant human
IL-2/mouse, plus one additional IL-2 dose on day 21 (Fig. 5b). In
the next experiment using the same initial leukemia dose, but with
ip GDTc injections, Donor 1 GDTc expansion was not as great;
15610
6 GDTc were administered ip in 10 mice on day 6 followed
by a second dose of 10610
6 in only 3 mice (Fig. 5b). IL-2 was
administered on GDTc injection days only. The Kaplan-Meier
survival curves show that under these conditions in this model,
GDTc therapy provided no survival advantage (Logrank/Mantel-
Cox, p=0.3563), whether GDTc were injected ip or iv. However,
we were able to detect GDTc in the bone marrow of infused mice
at necropsy (Fig. 5c) indicating that GDTc reached the primary
site of leukemia cell engraftment. For additional flow cytometry
data from this experiment, please see Supplementary Figure S9.
For the next experiment, we used a lower initial leukemia cell
dose (1610
6 EM-2eGFPluc, n=11) and earlier GDTc treatments,
with 15610
6 cells injected ip on day 2 and a further 2610
6 ip
given on day 6 (n=5, Fig. 6). In this experiment, IL-2 was
administered ip with GDTc injections and then weekly thereafter
to promote survival of injected GDTc.
We monitored bone marrow bioluminescence over time
(Fig. 6a). In this experiment, bioluminescence between treated
and untreated mice was similar at early time points, in contrast to
previous experiments (data not shown). However, of the three
survivors on d35, the treated mice had much lower signals than
untreated, suggesting that GDTc resulted in a lower leukemia
burden, hence longer survival. Flow cytometry data at the
experimental endpoint also showed a decreased eGFP+ cell
population in the two treated mice versus untreated animals (0%
and 2.8% compared to 5.5%, respectively). Overall, the endpoint
bone marrow data ranged considerably in the treated group (0% –
8.0%, mean 4.4% 63.1), rendering the difference between treated
and untreated groups insignificant (student’s t-test, p=0.13); in
contrast, untreated mice exhibited a highly consistent leukemia
burden 7.1% 61.4, suggesting that GDTc therapy did indeed
have some influence in the bone marrow (Fig. 6b). However, no
significant survival advantage was achieved (Fig. 6c, Logrank/
Mantel-Cox, p=0.1081).
To ensure that the injected GDTc were indeed functional, we
assessed the ability of EM-2eGFPluc targets to activate the cells on
injection days with the CD107 assay (data not shown). Cr
51 release
Figure 4. EM-2eGFPluc engraft the bone marrow in a novel in vivo xenogeneic Ph
+ leukemia model. a) NSG mice were injected with EM-
2eGFPluc iv on day 0. On day 21, mice were injected with luciferin, anesthetized and imaged using IVISH technology. Shown here are three mice that
received 2.5610
5 and two mice that were injected with 1610
5 EM-2eGFPluc on day 0. In total, 17 mice were used in this experiment: 3 per group at
doses of 1, 2.5, 5, 7.5 and 10610
5 EM-2eGFPluc; 1 mouse was injected with 0.4610
5 EM-2eGFPluc; 1 mouse was injected with PBS +0.2% BSA alone. b)
On day 28, mice were injected with luciferin, anesthetized and imaged using IVISH technology. Bioluminescence was quantified using Living Image
TM
software and bone marrow flux per mouse plotted against injected EM-2eGFPluc. Shown here are the results from the 5 groups of 3 mice described
in Fig. 4a. Bone marrow (BM) flux units are photons/second/square centimeters/steradian.
doi:10.1371/journal.pone.0016700.g004
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16700Figure 5. Higher gamma delta T cell levels result when they are injected intraperitoneally versus intravenously. a) Irradiated NSG mice
were injected with 0 (n=3 mice GDT only iv) or 1.5 million EM-2eGFPluc (n=6 mice) on day 0. On day 6, 3 mice were injected with 30 million Donor 2
GDTc intraperitoneally (IP); 6 mice were injected iv (IV+GDTonlyIV). Donor 2 GDTc had been cultured for 20 days prior to injection. Mice were
sacrificed on day 20, the indicated tissues were prepared for flow cytometric assessment. Gamma delta T cells were stained with anti-CD3 APC and
anti-CD45 PE antibodies. b) 1.5 million EM-2eGFPluc cells were injected intravenously into irradiated NSG mice (n=25). 30 million Donor 1 GDTc
(Isolation 13, days 15 and 21) were injected iv on days 6 and 12 post-leukemia cell injection, along with 100 IU recombinant human IL-2/mouse, plus
one additional IL-2 dose on day 21 (n=6, red line). 15 million GDTc (Isolation 25, day 15) were administered ip on day 6 (n=10, blue and green lines);
a second dose of 10 million (Isolation 25, day 21) was given on day 12 (n=3, green line). IL-2 was administered on GDTc injection days only (green
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targets. Shown in Fig. 6d are Cr
51 data for this particular
experiment. Percent lysis at 20:1 (blue) and 10:1 (red) E:T ratios
were 36.2% 61.9 (mean 6 SD) and 31.0% 62.0, respectively, on
culture day 17, and slightly higher at 38.5% 61.0 and 34.460.4%
on day 21, confirming GDTc cytotoxicity against EM-2eGFPluc
targets.
GDTc survived in the mice until the experimental endpoint, up
to 33 days after administration of the second GDTc dose. Weekly
blood samples were taken via saphenous vein on days 16, 23 and
30 post-leukemia cell injection. Blood was stained with anti-human
CD3 and anti-human CD45 antibodies to detect the presence of
GDTc (Fig. 6e). In 4 of 5 mice, GDTc numbers increased
dramatically by day 23; the mean was 0.13% 60.06 (6 SD) of live
cells compared to 0.06% 60.01 on day 16, but decreased again by
day 30, to an average of 0.01% 60.01. At endpoint, between days
33 and 39, GDTc were found in the blood of all five therapy mice
(0.25% 60.19, n=5); since these samples were obtained from
post-necropsy heart puncture, they could not be compared directly
to previous samples that had been obtained via saphenous vein of
live mice. EM-2eGFPluc blood levels were not significantly lower
in the treated group (data not shown, 0.24% 60.24 SD in treated
versus 0.31% 60.33 SD in untreated mice).
While GDTc could not be detected in the bone marrow of all
but one mouse (#202), they were found in the spleen (0.99%
62.11, n=5). Mouse #202 had exceptionally high GDTc levels at
necropsy (Supplementary Figure S10). Our data show that human
GDTc are able to survive at least 39 days in this mouse model.
Discussion
Several protocols are now available to expand GDTc in vitro;
most rely on synthetic phosphoantigens such as bromohydrin
pyrophosphate (IPH1101, formerly Phosphostim
TM) or aminobi-
sphosphonates like Zoledronate that preferentially expand the
Vc9Vd2 subset in the context of whole PBMCs [33,34]. The
purity of GDTc obtained using these protocols is variable;
however, this can be improved by GDTc sorting and culturing
with irradiated PBMC feeders in the presence of mitogen [35]. A
recently published protocol depletes PBMCs of CD4+ and CD8+
cells and, using anti-CD3 stimulation, subsequently expands
Vdelta1 and/or Vdelta2 GDTc, in proportion to their ratio in
peripheral blood [36]. In contrast, our protocol requires antibodies
only for the initial selection, but not for the further expansion, of
GDTc. Feeder cells are not required; these complicate a clinical
protocol by introducing extra handling, thereby increasing
workload and the potential for contamination. With our protocol,
we can expand GDTc to clinically relevant numbers; in many
cases, we can even drive expansion of the Vdelta1 or Vdelta2
subset irrespective of their proportion in donor blood (Siegers et al,
in press).
It will be important to establish whether it is possible to expand
patient GDTc with our protocol. Indeed, in the clinical setting, it
would be best to subject patient samples to a preliminary
expansion test in order to determine their responsiveness to this
protocol and thereby gauge the feasibility of generating clinically
relevant numbers of GDTc. To this end, it would also be advisable
to screen each patient’s GDTc against a panel of human AB sera
at the same time, to determine the optimum serum for clinical
expansion.
The majority of GDTc generated using our protocol are effector
memory cells, CD45RA
2, CD45RO
+ [32,37] and CD27
2 [32].
This is in accordance with GDTc expanded from imatinib-treated
CML patients, which are predominantly central memory
(CD45RA-CD27+) in peripheral blood, yet after expansion with
bromohydrin pyrophosphate attain the CD45RA-CD27- effector
memory phenotype (Helene Sicard, personal communication,
unpublished data). In contrast, in a recently published study, an
increase in late memory cytotoxic lymphocytes was found in
dasatinib-treated patients, as well as an overall increase in GDTc
levels compared to diagnosis [38], adding to a growing body of
evidence suggesting that individual TKIs have differing immuno-
modulatory properties in the context of CML [25].
In our cultures, high CD95
+ expression may indicate readiness
to undergo in vivo deletion [39]. We also observed high levels of
NKG2D and moderate CD56 and CD16 expression, all of which
are correlated with GDTc cytotoxicity [40,41,42]. Importantly,
cytotoxicity assays performed on injection days confirmed that
these in vitro-expanded GDTc were potent killers of EM-2eGFPluc
target cells.
As an important step towards validating our pre-clinical model
for cell therapy, we have demonstrated that in vitro-expanded
GDTc are specifically cytotoxic towards Ph
+ leukemia cells, but
not normal autologous peripheral blood cells or hematopoietic
progenitor cells.
Our rationale for developing a xenogeneic leukemia model, as
opposed to a murine model, to test GDTc therapy is because the
human Vc9Vd2 GDTc subset, which is cytotoxic to Ph
+
leukemia cells, does not exist in mice [43,44]. We chose the
NSG strain since engraftment of human hematopoietic cells in
these mice is superior compared to NODscid [45]. Even so,
irradiation of these mice prior to leukemia cell injection is
needed, as one experiment performed in the absence of
irradiation resulted in lesser and inconsistent leukemia cell
engraftment (data not shown). The use of bioluminescent
leukemia cells in this model provides several advantages: 1)
leukemia progression and regression can be easily monitored; 2)
leukemia burden can be quantified; and 3) less animals are
required because it is not necessary to sacrifice animals at several
time points to monitor disease. We chose to use EM-2eGFPluc
cells for this model because their engraftment is mainly localized
to the bone marrow, the site of hematopoeisis. Earlier attempts
using K562eGFPluc cells resulted in an unsatisfactory pathology,
with inconsistent tumour cell engraftment of other anatomical
locations and not bone marrow (data not shown), similar to a
recently published xenograft model using MM1 leukemic cells
[46]. Importantly, in that study, D’Asaro and colleagues show
impressive killing of zoledronate-pretreated IM-sensitive and -
resistant CML cells by patient-derived Vdelta2 GDTc in vitro and
in vivo. Though combination treatment of GDTc, zoledronate and
IL-2 in their xenograft model eradicated bioluminescence signals
and greatly improved survival, the in vivo model pathology in that
case did not resemble CML. [46]. Thus, they were unable to
address whether GDTc migrate to bone marrow and provide
defense at this critical anatomical location. Likewise, in xenograft
and blue). Survival curves were not significantly different (Log-rank/Mantel-Cox p=0.3563). c) Bone marrow from treated (T), untreated (U) and PBS
control mice was extracted and stained with anti-CD3APC and anti-CD45PE antibodies and then subject to flow cytometric analysis. A live cell gate
was made based on forward and side scatter properties; the GFP-negative population of live cells is shown here. This is a representative example of
bone marrow samples taken at endpoint from the experiment described in b (T single dose, blue line; U, black line). Bone marrow samples were
obtained from 2 PBS controls, 1 untreated and 7 treated mice in total.
doi:10.1371/journal.pone.0016700.g005
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PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e16700Figure 6. Gamma delta T cell therapy lowers bone marrow leukemia burden. a) 1 million EM-2eGFPluc cells were injected intravenously
into NSG mice (n=11). 15 million Donor 1 GDTc were injected intraperitoneally on day 2 and 2 million on day 6 post-leukemia cell injection (n=5). All
mice received 100 IU recombinant human IL-2 intraperitoneally on gamma delta T cell injection days and then weekly thereafter. IVISH imaging was
performed on the indicated days and bone marrow bioluminescence was quantified using Living Image
TM software. Untreated (blue) n=6 and
therapy (red) n=5, except on day 35, where untreated n=1 and treated n=2, since most mice were sacrificed between days 28 and 35. Shown are
mean luminescence 6 standard error. b) At experimental endpoint, bone marrow was extracted and GFP positive cells detected by flow cytometry.
Results from therapy mice are shown in red and untreated in blue (error bars represent standard error; n=5 and 5, respectively). c) Kaplan Meier
survival curve for the experiment described in a) and b), with no significant survival advantage achieved (untreated blue line (n=6) treated red (n=5);
Log-rank/Mantel-Cox, p=0.1081). d) Donor 1 gamma delta T cells were tested in Cr
51 release assays against EM-2eGFPluc targets on injection days for
the experiment shown in a)-c). Effectors and Cr
51-labeled targets were incubated at 20:1 (blue) and 10:1 (red) for 4 hours at 37uC and Cr
51 release
measured (n=1 donor in triplicate). Shown is the mean 6 standard deviation. These results are representative for gamma delta T cell cytotoxicity
measured on injection days in other therapy experiments (n=4 independent experiments in tripicate, 2 different donors). e) For the experiment
shown in a)-d), weekly blood samples were taken via saphenous vein and blood was stained with anti-human CD3 and anti-human CD45 antibodies
to detect gamma delta T cells on the indicated days. Gating was done on the live cell population in forward and side scatter. Individual treated mice
are indicated by number (n=5 treated mice in this experiment). Monitoring of gamma delta T cells in blood was performed in every therapy
experiment described (n=4 independent in vivo experiments).
doi:10.1371/journal.pone.0016700.g006
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injection of lung cancer cells and GDTc provided significant
survival advantages to treated mice, but the model did not
emulate human disease [36].
In early stages of our model system, leukemia engraftment
closely recapitulated human chronic phase CML; however, at later
points, aggressive disease resembled blast crisis, at which point
GDTc likely became overwhelmed, possibly accounting for the
lack of survival advantage in treated mice. Our model could be
potentially improved by administration of IM, to better emulate
the situation in the majority of CML patients. Use of GDTc plus
aminobisphosphanates such as zoledronate or aledronate may
have dramatically improved outcomes, as observed in other
experimental systems [46,47]. A drawback to our system was that
GDTc were injected in the absence of other human immune cells
that could play an important role in augmenting antitumor
cytotoxicity and GDTc survival; thus, this model may underesti-
mate GDTc potential.
At best, we could administer only two doses of GDTc therapy
due to ethics board restrictions allowing us only one blood draw
every two months from the same donor. Increased frequency of
access to blood from the same donor would have allowed for more
therapy doses and possibly improved our chances of obtaining a
significant response. Indeed, Kabelitz and colleagues saw signif-
icantly improved survival with increasing frequency of GDTc
therapy in both their MeWo melanoma and PancTu1 pancreatic
adenocarcinoma models [47]. They were able to generate multiple
GDTc doses over time by using re-stimulation and irradiated
feeder cells. Our protocol is much less involved, but unfortunately,
we are unable to recover frozen and thawed polyclonal GDTc
batches to use at will. Overcoming this obstacle would provide a
great advantage to the GDTc field at large.
Despite these limitations, a measure of success was achieved
with GDTc therapy as evidenced by the decreased leukemia
burden in the bone marrow of some treated mice. Indeed, bone
marrow leukemia was not necessarily responsible for the demise of
mice in these experiments; rather, migration of leukemia cells to
the central nervous system late in the experiments caused paralysis
in most, at which point the mice were sacrificed on humane
grounds. Again, IM alone or in combination with GDTc
activators might prevent this migration and improve the model
as well as conditions for therapy.
We are the first to formally document long-term survival of
GDTc in the bone marrow in a xenograft setting. This is
significant, as primary GDTc longevity in vitro is limited to 14–21
days, depending on the protocol. In our therapy experiments,
GDTc were cultured 16–21 days before injection and were still
found alive in the mice up to 33 days later. This is similar to results
obtained by Kabelitz and colleagues, who injected multiple doses
of GDTc clones and found small numbers remaining in peritoneal
exudates and spleen cells in SCID mice up to 30 days post-
injection [47]. Indeed, we were very encouraged to find GDTc in
the bone marrow at endpoint in most of our experiments. Our
inability to detect GDTc in some cases might have been partly due
to sample preparation, since unpredictable endpoints sometimes
led to sample fixation for various lengths of time. Also the time
lapse between the final GDTc injection and experimental
endpoint likely played a role. GDTc were detectable in bone
marrow when the second GDTc dose was on day 12 (Fig. 5B, red
line), yet not consistently in an experiment where GDTc were last
administered on day 6 (Fig. 6). Importantly, we found no evidence
of graft-versus-host disease in these mice, as high numbers of
human GDTc, up to two doses of 30 million per dose, were well
tolerated. However, this may become an issue with increasing
numbers and frequency of doses, as Kabelitz and colleagues
observed beyond five doses of 10 million GDTc in their mouse
models [47].
In summary, we have devised a protocol to expand GDTc to
clinically relevant numbers, developed a bioluminescent xenoge-
neic model of Ph
+ leukemia and tested GDTc therapy in this
model. Although no significant survival advantage was achieved
under our conditions, GDTc therapy was well tolerated and
GDTc survived for extended periods in the mice. GDTc were
often found in bone marrow and therapy decreased leukemia
burden in some treated mice, showing that GDTc migrate to, and
are active at the site of leukemia. We are currently optimizing
treatment regimens and further exploring GDTc cytotoxicity
mechanisms and migration in this model.
Supporting Information
Table S1 Purity, passaging and viability of gamma
delta T cell cultures derived from Donor 1. Gamma delta
T cells were isolated from peripheral blood of Donor 1 and
cultured as described in Materials and Methods. d = day; bkg adj
= background adjusted (unstained control values were subtracted
from those of stained samples); GDT = gamma delta T cell
antigen receptor positive cells; Vd1 = Vdelta1 and Vd2 =
Vdelta2 are indicated for cultures that were not stained with anti-
GDT antibody; AB = alpha beta T cell antigen receptor positive
cells; * days of initial exposure to Concanavalin A; **Calculated
from %CD3 – %AB, since GD TCR staining did not work; -fold
exp (d total) = -fold expansion (total number of days in culture).
Viability was calculated: (live/(live+dead)) x 100%. Live and dead
cells were distinguished via Trypan Blue exclusion.
(DOC)
Table S2 Flow cytometry values showing percent pos-
itive and corresponding mean fluorescent intensity for
various surface markers. Gamma delta T cell cultures were
harvested and stained for the indicated surface markers on days 15
and 21 of culture. d = day; mfi = mean fluorescence intensity;
Vd2 = Vdelta2 T cell antigen receptor. Table values are for flow
cytometric data shown in Fig. 1B.
(DOC)
Figure S1 Supporting flow cytometry data for gamma
delta T cell culture derived from Donor 1 isolation#6. d
= culture day; GD TCR = gamma delta T cell antigen receptor;
AB TCR = alpha beta T cell antigen receptor. The upper panels
show purity of gamma delta T cells isolated via positive selection
(MACS magnetic sorting, Miltenyi). The lower panels show
staining of cells harvested on culture day 17. Live lymphocytes
were gated in forward and side scatter (not shown). Negative
controls in red are the unstained peripheral blood mononuclear
cell fraction before sorting (preMACS, top panels) or unstained
cells (bottom left). On the upper left, gamma delta T cells are
bound to beads that are FITC labeled. This fraction was also
labeled with anti-AB TCR antibody (top right panel). Percent
positive GD TCR and AB TCR and histogram gate are indicated.
The lower right panel is a dot blot indicating the percentage of AB
TCR positive cells in culture on day 17.
(TIFF)
Figure S2 Supporting flow cytometry data for gamma
delta T cell culture derived from Donor 1 isolation#11.
d = culture day; GD TCR = gamma delta T cell antigen
receptor; AB TCR = alpha beta T cell antigen receptor. The
upper panels show purity of gamma delta T cells isolated via
positive selection (MACS magnetic sorting, Miltenyi). On the
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labeled. This fraction was also labeled with anti-AB TCR antibody
(top right panel). Gating and percent positive GD TCR and AB
TCR are indicated. The middle and lower panels show staining of
cells harvested on culture days 12 and 18, respectively. Live cells
were gated in forward and side scatter (not shown). Negative
controls in red are the unstained peripheral blood mononuclear
cell fraction before sorting (preMACS, top panels) or unstained
cells (middle and bottom left).
(TIFF)
Figure S3 Supporting flow cytometry data for gamma
delta T cell culture derived from Donor 1 isolation#13.
d = culture day; GD TCR = gamma delta T cell antigen
receptor; AB TCR = alpha beta T cell antigen receptor; Vdelta2
= Vdelta2 GD TCR. The upper panels show purity of gamma
delta T cells isolated via positive selection (MACS magnetic
sorting, Miltenyi). On the upper left, gamma delta T cells are
bound to beads that are FITC labeled. This fraction was also
labeled with anti-AB TCR antibody (top right panel). Gating and
percentage of cells positive for the indicated receptors are shown.
The middle and lower panels show staining of cells harvested on
culture days 8, 15 and 21, respectively. Live cells were gated in
forward and side scatter (not shown). Negative controls in red are
the unstained peripheral blood mononuclear cell fraction before
sorting (preMACS, top left panel), unstained MACS positive
fraction unstained (MACS+, top right) or unstained cells (all other
panels).
(TIFF)
Figure S4 Supporting flow cytometry data for gamma
delta T cell culture derived from Donor 1 isolation#25.
d = culture day; GD TCR = gamma delta T cell antigen
receptor; AB TCR = alpha beta T cell antigen receptor; Vdelta1
= Vdelta1 GD TCR; Vdelta2 = Vdelta2 GD TCR. The upper
panels show purity of gamma delta T cells isolated via positive
selection (MACS magnetic sorting, Miltenyi). On the upper left,
gamma delta T cells are bound to beads that are FITC labeled.
This fraction was also labeled with anti-AB TCR antibody (top
right panel). Gating and percentage of cells positive for the
indicated receptors are shown. The middle and lower panels show
staining of cells harvested on culture days 10, 15 and 21,
respectively. Live cells were gated in forward and side scatter (not
shown). Negative controls in red are the unstained peripheral
blood mononuclear cell fraction before sorting (preMACS, top
panel) or unstained cells (all other panels).
(TIFF)
Figure S5 Supporting flow cytometry data for gamma
delta T cell culture derived from Donor 1 isolation#34.
d = culture day; GD TCR = gamma delta T cell antigen
receptor; AB TCR = alpha beta T cell antigen receptor; Vdelta1
= Vdelta1 GD TCR; Vdelta2 = Vdelta2 GD TCR. The upper
panels show purity of gamma delta T cells isolated via positive
selection (MACS magnetic sorting, Miltenyi). On the upper left,
gamma delta T cells are bound to beads that are FITC labeled.
This fraction was also labeled with anti-AB TCR antibody (top
right panel). Gating and percentage of cells positive for the
indicated receptors are shown. The middle and lower panels show
staining of cells harvested on culture days 9 and 16, respectively.
Live cells were gated in forward and side scatter (not shown).
Negative controls in red are the unstained peripheral blood
mononuclear cell fraction before sorting (preMACS, top left panel)
or unstained cells (bottom left panel).
(TIFF)
Figure S6 Titration of anti-CD27 APC antibody. Aliquots
of the MACS negative fraction (9 x 10
5 cells/aliquot) were stained
with the indicated dilutions of anti-CD27 APC antibody in 20 ml
for 20 min, washed and subject to flow cytometry. The negative
control (red line) is unstained MACS negative cells. The upper
panel shows histogram overlays of all dilutions tested. Mean
fluorescence intensity (mfi) values are indicated. The lower panel
shows overlays of the unstained control (red) and the 1:100
dilution used in Figure 1b (blue).
(TIFF)
Figure S7 Transduced and parental leukemia cell lines
elicit similar CD107 mobilization in gamma delta T
cells. CD107 experiments were performed using Donor 3 gamma
delta T cells and target lines EM-2 and EM-2eGFPluc. All samples
had been stained using anti-human CD107aAlexa647. Live GDTc
were gated; shown is a representative example, n=3 different
donors.
(TIFF)
Figure S8 Transduced RAJI cells do not activate gamma
delta T cells. CD107 experiments were performed using Donor
2 gamma delta T cells and target lines EM-2, RAJI and
RAJIeGFPluc. All samples had been stained using anti-human
CD107aAlexa647 and anti-Vdelta2PE antibodies. Cells were
gated on live Vdelta2+ GDTc; mean fluorescence intensity values
are shown in red and %CD107 in black.
(TIFF)
Figure S9 Additional bone marrow flow cytometry data
from therapy experiment shown in Fig. 5c. Bone marrow
from treated (T, n = 7), untreated (U, n = 1) and PBS control (n
= 2) mice was extracted and stained with anti-CD3APC and anti-
CD45PE antibodies and then subject to flow cytometric analysis.
The live cell gate was based on forward and side scatter properties;
the GFP-negative population of live cells is shown. The percentage
of CD3/CD45 positive cells is indicated. * mice that received two
gamma delta T cell doses.
(TIFF)
Figure S10 Gamma delta T cells are found in spleen,
blood and bone marrow. Flow cytometric analysis showing
gamma delta T cell engraftment in the tissues of one therapy
mouse (#202) at endpoint in the experiment shown in Figure 6.
One untreated mouse (#199) is shown as a negative control. Gates
and percentages are indicated.
(TIFF)
Acknowledgments
We would like to thank our healthy donors, as it would have been
impossible to carry out this work without them. The animal care facility at
UHN, in particular Jean Flanagan, deserves many thanks for advice and
assistance. We thank Mileidys Alvarez for initial help with GDTc cultures,
Simone Helke for helping with flow cytometry at the outset, Gustavo
Yanarelli and Christiane Mallett for help with statistics and Sonia
Montanari for lending a hand with bone marrows in some experiments.
A.K. holds the Gloria and Seymour Chair in Cell Therapy and
Transplantation at University Health Network and the University of
Toronto.
Author Contributions
Conceived and designed the experiments: GMS AK. Performed the
experiments: GMS TCF AMM XW. Analyzed the data: GMS AMM YK.
Contributed reagents/materials/analysis tools: TCF JAM. Wrote the
paper: GMS AK.
Gamma Delta T Cell Therapy in Ph
+ Leukemia Model
PLoS ONE | www.plosone.org 12 February 2011 | Volume 6 | Issue 2 | e16700References
1. Lamb LS, Jr., Lopez RD (2005) gammadelta T cells: a new frontier for
immunotherapy? Biol Blood Marrow Transplant 11: 161–168.
2. Ensslin AS, Formby B (1991) Comparison of cytolytic and proliferative activities
of human gamma delta and alpha beta T cells from peripheral blood against
various human tumor cell lines. J Natl Cancer Inst 83: 1564–1569.
3. Zheng BJ, Chan KW, Im S, Chua D, Sham JS, et al. (2001) Anti-tumor effects of
human peripheral gammadelta T cells in a mouse tumor model. Int J Cancer 92:
421–425.
4. Kabelitz D, Wesch D, He W (2007) Perspectives of gammadelta T cells in tumor
immunology. Cancer Res 67: 5–8.
5. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, et al. (2008) Chemokine
receptors expression and migration potential of tumor-infiltrating and
peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma
patients. J Immunother 31: 313–323.
6. Wright A, Lee JE, Link MP, Smith SD, Carroll W, et al. (1989) Cytotoxic T
lymphocytes specific for self tumor immunoglobulin express T cell receptor delta
chain. J Exp Med 169: 1557–1564.
7. Freedman MS, D’Souza S, Antel JP (1997) gamma delta T-cell-human glial cell
interactions. I. In vitro induction of gammadelta T-cell expansion by human
glial cells. J Neuroimmunol 74: 135–142.
8. Vollenweider I, Vrbka E, Fierz W, Groscurth P (1993) Heterogeneous binding
and killing behaviour of human gamma/delta-TCR+ lymphokine-activated
killer cells against K562 and Daudi cells. Cancer Immunol Immunother 36:
331–336.
9. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, et al. (2000)
Stimulation of gammadelta T cells by aminobisphosphonates and induction of
antiplasma cell activity in multiple myeloma. Blood 96: 384–392.
10. Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, et al. (2006) Flow
cytometric assessment of autologous gammadelta T cells in patients with acute
myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin
Cytom 70: 379–390.
11. Lamb LS, Jr., Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, et al.
(1996) Increased frequency of TCR gamma delta + T cells in disease-free
survivors following T cell-depleted, partially mismatched, related donor bone
marrow transplantation for leukemia. J Hematother 5: 503–509.
12. Lamb LS, Jr., Musk P, Ye Z, van Rhee F, Geier SS, et al. (2001) Human
gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the
absence of an allogeneic response. Bone Marrow Transplant 27: 601–606.
13. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, et al. (2007) Safety
profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T
cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol
Immunother 56: 469–476.
14. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K (2010) Complete
remission of lung metastasis following adoptive immunotherapy using activated
autologous gammadelta T-cells in a patient with renal cell carcinoma.
Anticancer Res 30: 575–579.
15. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, et al. (2010) A phase I
study of adoptive immunotherapy for recurrent non-small-cell lung cancer
patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37:
1191–1197.
16. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa
staining. Nature 243: 290–293.
17. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, et al.
(1984) Philadelphia chromosomal breakpoints are clustered within a limited
region, bcr, on chromosome 22. Cell 36: 93–99.
18. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, et al.
(1982) A cellular oncogene is translocated to the Philadelphia chromosome in
chronic myelocytic leukaemia. Nature 300: 765–767.
19. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of
a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive
cells. Nat Med 2: 561–566.
20. Deininger MW (2008) Milestones and monitoring in patients with CML treated
with imatinib. Hematology Am Soc Hematol Educ Program. pp 419–426.
21. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, et al. (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
N Engl J Med 355: 2408–2417.
22. Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors
in chronic myeloid leukemia and recent therapeutic strategies to overcome
resistance. Hematology Am Soc Hematol Educ Program. pp 461–476.
23. Mustjoki S, Rohon P, Rapakko K, Jalkanen S, Koskenvesa P, et al. (2010) Low
or undetectable numbers of Philadelphia chromosome-positive leukemic stem
cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete
cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 24:
219–222.
24. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, et al. (2005) Effect of a
p210 multipeptide vaccine associated with imatinib or interferon in patients with
chronic myeloid leukaemia and persistent residual disease: a multicentre
observational trial. Lancet 365: 657–662.
25. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, et al. (2010) Mono/
oligoclonal T and NK cells are common in chronic myeloid leukemia patients at
diagnosis and expand during dasatinib therapy. Blood 116: 772–782.
26. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, et al. (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib
therapy. Leukemia 23: 1398–1405.
27. Keating A MP, Bernstein ID, Papayannopoulou T, Raskind W, Singer JW ()
EM-2 and EM-3: two new Ph’+ myeloid cell lines. In: GDM PA, ed. Symposia
on Molecular and Cellular Biology, New Series; 1983; UCLA. New York: Alan
R. Liss. pp 513–520.
28. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L (2005) Coordinate dual-
gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters.
Nat Biotechnol 23: 108–116.
29. Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, et al. (2004)
Bioluminescent imaging of a marking transgene and correction of Fabry mice
by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci U S A
101: 16909–16914.
30. Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, et al. (2005) KHYG-1, a
model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 33:
1160–1171.
31. McCoy JL, Herberman RB, Rosenberg EB, Donnelly FC, Levine PH, et al.
(1973) 51 Chromium-release assay for cell-mediated cytotoxicity of human
leukemia and lymphoid tissue-culture cells. Natl Cancer Inst Monogr 37: 59–67.
32. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, et al. (2003) Differentiation of
effector/memory Vdelta2 T cells and migratory routes in lymph nodes or
inflammatory sites. J Exp Med 198: 391–397.
33. Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, et al. (2001) Chemical
synthesis and biological activity of bromohydrin pyrophosphate, a potent
stimulator of human gamma delta T cells. J Biol Chem 276: 18337–18344.
34. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, et al.
(2009) Peripheral blood monocytes are responsible for gammadelta T cell
activation induced by zoledronic acid through accumulation of IPP/DMAPP.
Br J Haematol 144: 245–250.
35. Salot S, Bercegeay S, Dreno B, Saiagh S, Scaglione V, et al. (2009) Large scale
expansion of Vgamma9Vdelta2 T lymphocytes from human peripheral blood
mononuclear cells after a positive selection using MACS ‘‘TCR gamma/delta+
T cell isolation kit’’. J Immunol Methods 347: 12–18.
36. Dokouhaki P, Han M, Joe B, Li M, Johnston MR, et al. (2010) Adoptive
immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A
new approach. Cancer Lett 297: 126–136.
37. Braakman E, Sturm E, Vijverberg K, van Krimpen BA, Gratama JW, et al.
(1991) Expression of CD45 isoforms by fresh and activated human gamma delta
T lymphocytes and natural killer cells. Int Immunol 3: 691–697.
38. Rohon P, Porkka K, Mustjoki S (2010) Immunoprofiling of patients with chronic
myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Eur J Haematol 85: 387–398.
39. Poccia F, Boullier S, Lecoeur H, Cochet M, Poquet Y, et al. (1996) Peripheral V
gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial
antigens in asymptomatic HIV-1-infected persons. J Immunol 157: 449–461.
40. Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, et al.
(2008) Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lym-
phocytes display potent antitumor activity toward human squamous cell
carcinoma. Clin Cancer Res 14: 4232–4240.
41. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, et al. (2004)
FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector
cells with different responses and activation pathways. Blood 104: 1801–1807.
42. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK
cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:
727–729.
43. Hayday AC (2000) [gamma][delta] cells: a right time and a right place for a
conserved third way of protection. Annu Rev Immunol 18: 975–1026.
44. Bonneville M, Scotet E (2006) Human Vgamma9Vdelta2 T cells: promising new
leads for immunotherapy of infections and tumors. Curr Opin Immunol 18:
539–546.
45. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. (2005) Human
lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null
mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:
6477–6489.
46. D’Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, et al. (2010) V
gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-
sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous
leukemia cells. J Immunol 184: 3260–3268.
47. Kabelitz D, Wesch D, Pitters E, Zoller M (2004) Characterization of tumor
reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in
SCID mice in vivo. J Immunol 173: 6767–6776.
Gamma Delta T Cell Therapy in Ph
+ Leukemia Model
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e16700